Use of anakinra in severe COVID-19: A case report
Giovanni Filocamo, Davide Mangioni, Paola Tagliabue, Stefano Aliberti, Giorgio Costantino, Francesca Minoia, Alessandra Bandera
Abstract
Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).
Topics & Concepts
AnakinraCoronavirus disease 2019 (COVID-19)Cytokine stormMedicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseAntagonistCytokineIntensive care medicineInternal medicineReceptorVirologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesInflammasome and immune disordersDermatological and COVID-19 studies